CN106727422B - 一种聚对二氧环己酮为核的核-壳双层微球及其制备方法和应用 - Google Patents
一种聚对二氧环己酮为核的核-壳双层微球及其制备方法和应用 Download PDFInfo
- Publication number
- CN106727422B CN106727422B CN201710138619.2A CN201710138619A CN106727422B CN 106727422 B CN106727422 B CN 106727422B CN 201710138619 A CN201710138619 A CN 201710138619A CN 106727422 B CN106727422 B CN 106727422B
- Authority
- CN
- China
- Prior art keywords
- core
- polydioxanone
- microballoon
- shell structure
- structure copolymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 title claims abstract description 93
- 239000000622 polydioxanone Substances 0.000 title claims abstract description 93
- 239000011258 core-shell material Substances 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 229920001577 copolymer Polymers 0.000 title claims description 46
- 239000003814 drug Substances 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 7
- 239000011259 mixed solution Substances 0.000 claims description 48
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 42
- 239000000839 emulsion Substances 0.000 claims description 42
- 239000000725 suspension Substances 0.000 claims description 41
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 claims description 28
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 239000002202 Polyethylene glycol Substances 0.000 claims description 21
- 229920001223 polyethylene glycol Polymers 0.000 claims description 21
- 238000003756 stirring Methods 0.000 claims description 21
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 18
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 17
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 16
- 239000007864 aqueous solution Substances 0.000 claims description 15
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 14
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 13
- 238000004945 emulsification Methods 0.000 claims description 12
- 238000009156 water cure Methods 0.000 claims description 12
- OMOVVBIIQSXZSZ-UHFFFAOYSA-N [6-(4-acetyloxy-5,9a-dimethyl-2,7-dioxo-4,5a,6,9-tetrahydro-3h-pyrano[3,4-b]oxepin-5-yl)-5-formyloxy-3-(furan-3-yl)-3a-methyl-7-methylidene-1a,2,3,4,5,6-hexahydroindeno[1,7a-b]oxiren-4-yl] 2-hydroxy-3-methylpentanoate Chemical compound CC12C(OC(=O)C(O)C(C)CC)C(OC=O)C(C3(C)C(CC(=O)OC4(C)COC(=O)CC43)OC(C)=O)C(=C)C32OC3CC1C=1C=COC=1 OMOVVBIIQSXZSZ-UHFFFAOYSA-N 0.000 claims description 11
- 239000003995 emulsifying agent Substances 0.000 claims description 11
- 235000014655 lactic acid Nutrition 0.000 claims description 9
- 239000004310 lactic acid Substances 0.000 claims description 9
- 241000790917 Dioxys <bee> Species 0.000 claims description 8
- 238000005292 vacuum distillation Methods 0.000 claims description 8
- -1 which is made Substances 0.000 claims description 8
- WHBMMWSBFZVSSR-UHFFFAOYSA-N R3HBA Natural products CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims description 6
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 claims description 6
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 6
- 239000004626 polylactic acid Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 4
- 239000003599 detergent Substances 0.000 claims description 4
- 239000004005 microsphere Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- OBNCKNCVKJNDBV-UHFFFAOYSA-N ethyl butyrate Chemical compound CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 claims description 2
- 238000007711 solidification Methods 0.000 claims description 2
- 230000008023 solidification Effects 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- REKYPYSUBKSCAT-UHFFFAOYSA-N 3-hydroxypentanoic acid Chemical class CCC(O)CC(O)=O REKYPYSUBKSCAT-UHFFFAOYSA-N 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 abstract description 4
- 238000006731 degradation reaction Methods 0.000 abstract description 4
- 239000011257 shell material Substances 0.000 abstract description 4
- 239000002537 cosmetic Substances 0.000 abstract description 3
- 238000013268 sustained release Methods 0.000 abstract description 3
- 239000012730 sustained-release form Substances 0.000 abstract description 3
- 230000000975 bioactive effect Effects 0.000 abstract description 2
- 238000013270 controlled release Methods 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 230000003416 augmentation Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 210000004872 soft tissue Anatomy 0.000 abstract 1
- 239000000463 material Substances 0.000 description 12
- 238000003825 pressing Methods 0.000 description 9
- 238000010586 diagram Methods 0.000 description 6
- QQZOPKMRPOGIEB-UHFFFAOYSA-N 2-Oxohexane Chemical compound CCCCC(C)=O QQZOPKMRPOGIEB-UHFFFAOYSA-N 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000009826 distribution Methods 0.000 description 4
- 239000011805 ball Substances 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 238000005253 cladding Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002085 enols Chemical class 0.000 description 2
- 239000011806 microball Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical class ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- SORGMJIXNUWMMR-UHFFFAOYSA-N lanthanum(3+);propan-2-olate Chemical compound [La+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] SORGMJIXNUWMMR-UHFFFAOYSA-N 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011824 nuclear material Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- UQGPCEVQKLOLLM-UHFFFAOYSA-N pentaneperoxoic acid Chemical compound CCCCC(=O)OO UQGPCEVQKLOLLM-UHFFFAOYSA-N 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
- A61K8/025—Explicitly spheroidal or spherical shape
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/85—Polyesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
- A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
本发明涉及一种聚对二氧环己酮为核的核‑壳双层微球及其制备方法和应用,属于生物医药技术领域,本发明提供了一种聚对二氧环己酮为核的核‑壳双层微球及其制备方法,该方法主要包括聚对二氧环己酮微球的制备及以该微球为核制备具有核‑壳结构的双层微球,该方法操作简单、重复性好、成本低,且制备过程对环境友好。制得的微球粒径大小相近、可控,安全可降解,组织相容性好,且降解缓慢,降解时间可根据壳材料的种类和核‑壳材料添加比例进行调控。该微球可广泛用于缓释或控释药物和生物活性物质、化妆品、软组织充填和修复等领域。
Description
技术领域
本发明属于生物医药技术领域,具体涉及一种聚对二氧环己酮为核的核-壳双层微球及其制备方法和应用。
背景技术
美国的Green B.X.和Wurster D.E.是微球技术的先驱,从1957年至今已有六十年的历史,最初是将微球技术用于制造压敏式炭复写纸,后逐渐拓展到了食品、药品、化妆品、感光材料及纺织等领域,随着科学技术的不断发展,人们对药品制剂的要求逐渐提高,微球作为一种新型控释、缓释给药体系(DDS)越来越多得到关注和广泛应用,药物经微球化、微囊化以后,可防止其在空气中氧化及分解,降低对人体脏器的刺激,通过缓释,可以减少药物用量并延长药效。然而,传统的单层微球制剂存在着一定缺点,例如,释放速率较快、药物突释等。现在,微球制备多集中在一些天然高分子材料、半合成高分子材料和合成高分子材料,如海藻酸钠、壳聚糖、透明质酸钠、CMC、HPMC、PLGA、PLA、PLLA、POE等。然而这些材料制备的微球,要么降解时间很快,要么降解时间很慢或无法降解。
因此,急需一种可以解决单层微球的突释与封包率低及不能调控缓释时间等问题的材料及其制备方法。
发明内容
有鉴于此,本发明的目的在于:(1)提供一种聚对二氧环己酮为核的核-壳双层微球的制备方法;(2)提供一种聚对二氧环己酮为核的核-壳双层微球;(3)提供一种聚对二氧环己酮为核的核-壳双层微球的应用。
为达到上述目的,本发明提供如下技术方案:
1、一种聚对二氧环己酮为核的核-壳双层微球的制备方法,包括如下步骤:
(1)将聚对二氧环己酮加入六氟异丙醇中至所述聚对二氧环己酮完全溶解,再加入溶剂A搅拌后,滴加到乳化剂中得混合溶液,所述混合溶液经分散、固化后,制得含有聚对二氧环己酮微球的乳化液;
(2)将步骤(1)中制得的乳化液进行负压蒸馏处理至所述乳化液中六氟异丙醇和溶剂A挥发,制得悬浮液;
(3)将步骤(2)中制得的悬浮液进行离心、洗涤、干燥后,制得聚对二氧环己酮微球;
(4)将物质B加入溶剂A中至所述物质B完全溶解,然后加入步骤(3)中制备的聚对二氧环己酮微球,搅拌后滴加到乳化剂中得混合溶液,所述混合溶液经分散、固化后,制得含有聚对二氧环己酮为核的核-壳双层微球的乳化液;
(5)将步骤(4)中制得的乳化液进行负压蒸馏处理至所述乳化液中溶剂A挥发,制得悬浮液;
(6)将步骤(5)中制得的悬浮液进行离心、洗涤、干燥后,制得聚对二氧环己酮为核的核-壳双层微球;
所述溶剂A为二氯甲烷,三氯甲烷或四氯化碳中的一种或几种;所述物质B为聚乳酸、聚左乳酸、聚乳酸-羟基乙酸共聚物、聚已内酯、聚羟基丁酸酯或3-羟基丁酸酯和3-羟基戊酸酯的共聚物中的一种或几种。
进一步,步骤(1)中,所述聚对二氧环己酮和六氟异丙醇的质量体积比(g/mL)为1~10:100;所述六氟异丙醇与溶剂A的体积比为1:1~3:1;所述乳化剂为聚乙烯醇水溶液或聚乙二醇水溶液中的一种,所述聚对二氧环己酮和所述乳化剂中溶质的质量比为2:1~1:2。
进一步,步骤(1)和步骤(4)中,所述分散、固化具体为室温下以4000~7000rpm均质搅拌至乳化完全后加入体积为所述混合溶液2~5倍的水固化微球,所述水的温度为1~5℃。
进一步,步骤(2)中,所述负压蒸馏处理为在55℃,0.06~0.09MPa条件下蒸馏30~60min。
进一步,步骤(3)中,所述离心为在4000rpm下离心3min;所述洗涤用洗涤剂是质量分数为70~75%的乙醇水溶液,所述乙醇水溶液和悬浮液的体积比为10:1~2:1;所述干燥为喷雾干燥,具体条件为100℃,功率为4kW,进料量为350~450mL/min。
进一步,步骤(4)中,所述物质B和溶剂A的质量体积比(g/mL)为1~10:100;所述乳化剂为聚乙烯醇水溶液或聚乙二醇水溶液中的一种,所述物质B和所述乳化剂中溶质的质量比为2:1~1:2。
进一步,步骤(5)中,所述负压蒸馏处理为在55~65℃,0.06~0.09MPa条件下蒸馏30~60min。
进一步,步骤(6)中,所述离心为在4000r/min下离心3min;所述洗涤用洗涤剂是质量分数为70~75%的乙醇水溶液,所述乙醇水溶液和悬浮液的体积比为10:1~2:1;所述干燥为喷雾干燥,具体条件为100~120℃,功率为4kW,进料量为350~450mL/min。
2、由所述的方法制备的聚对二氧环己酮为核的核-壳双层微球。
3、所述的聚对二氧环己酮为核的核-壳双层微球作为载药微球的应用。
本发明的有益效果在于:本发明提供了一种聚对二氧环己酮为核的核-壳双层微球及其制备方法,该方法操作简单、重复性好、成本低,且制备过程对环境友好。其中,所用的聚对二氧环己酮是一种具有良好水解性和极好的生物相容性、生物可吸收性的生物可降解材料。聚对二氧环己酮聚合物分子链中的酯键使其具有优异的生物降解性,醚键和CH2基团使其具有良好的柔韧性,于上个世纪70年代被美国食品及药品管理局(FDA)批准为医用可吸收手术缝合线的基体材料,以其为原料制得的微球粒径大小相近、可控,安全可降解,组织相容性好,且降解缓慢,降解时间可根据壳材料的种类和核-壳材料添加比例进行调控,解决了单层微球的突释与封包率低等问题。该微球不仅可用于DDS体系,更可以应用于生物组织工程领域,作为一种生物组织工程支架,细胞可在支架上生长、增殖,可以起到软组织局部充填和修复的作用,或直接用于局部靶组织栓塞治疗,另外,双层微球也可应用于化妆品领域,可载生物活性物质、刺激性气味成分等,进一步拓展了聚对二氧环己酮在医药及其他领域的应用。
附图说明
为了使本发明的目的、技术方案和有益效果更加清楚,本发明提供如下附图进行说明:
图1为实施例1中制备的聚对二氧环己酮为核的核-壳双层微球的扫描电镜图;
图2为实施例1中制备的聚对二氧环己酮为核的核-壳双层微球的荧光显微镜图;
图3为实施例1中所用原料聚对二氧环己酮的XRD图;
图4为实施例1中所用原料聚左乳酸的XRD图;
图5为实施例1中制备的聚对二氧环己酮为核的核-壳双层微球的XRD图;
图6为实施例5中制备的聚对二氧环己酮微球的粒径分布图;
图7为实施例5中制备的聚对二氧环己酮为核的核-壳双层微球的粒径分布图。
具体实施方式
下面将结合附图,对本发明的优选实施例进行详细的描述。
实施例1
(1)按聚对二氧环己酮和六氟异丙醇的质量体积比(g/mL)为8:100将聚对二氧环己酮加入六氟异丙醇中至所述聚对二氧环己酮完全溶解,再加入三氯甲烷搅拌后,滴加到聚乙烯醇水溶液中得混合溶液,此时,混合溶液中六氟异丙醇和三氯甲烷的体积比为2.5:1,聚对二氧环己酮和聚乙烯醇水溶液中聚乙烯醇的质量比为1:1,将所述混合溶液以6000rpm均质搅拌至乳化完全后加入体积为所述混合溶液2倍的水固化微球,所述水的温度为2℃,制得含有聚对二氧环己酮微球的乳化液;
(2)将步骤(1)中制得的乳化液在55℃,0.08MPa条件下蒸馏30min至所述乳化液中六氟异丙醇和三氯甲烷挥发,制得悬浮液;
(3)将步骤(2)中制得的悬浮液在4000rpm下离心3min后,用体积为所述悬浮液8倍的质量分数为75%的乙醇水溶液进行洗涤,然后在100℃,功率为4kW,进料量为400mL/min条件下进行喷雾干燥,制得聚对二氧环己酮微球;
(4)按聚左乳酸和三氯甲烷的质量体积比(g/mL)为8:100将聚左乳酸加入三氯甲烷中至所述聚左乳酸完全溶解,然后加入步骤(3)中制备的聚对二氧环己酮微球,搅拌后滴加到聚乙烯醇水溶液中得混合溶液,此时,混合溶液中聚左乳酸和聚乙烯醇水溶液中聚乙烯醇的质量比为1:1,将所述混合溶液以5000rpm均质搅拌至乳化完全后加入体积为所述混合溶液2倍的水固化微球,所述水的温度为2℃,制得含有聚对二氧环己酮为核的核-壳双层微球的乳化液;
(5)将步骤(4)中制得的乳化液在62℃,0.08MPa条件下蒸馏40min至所述乳化液中三氯甲烷挥发,制得悬浮液;
(6)将步骤(5)中制得的悬浮液在4000rpm下离心3min后,用体积为所述悬浮液8倍的质量分数为75%的乙醇水溶液进行洗涤,然后在100℃,功率为4kW,进料量为400mL/min条件下进行喷雾干燥,制得聚对二氧环己酮为核的核-壳双层微球。
实施例2
(1)按聚对二氧环己酮和六氟异丙醇的质量体积比(g/mL)为1:100将聚对二氧环己酮加入六氟异丙醇中至所述聚对二氧环己酮完全溶解,再加入二氯甲烷搅拌后,滴加到聚乙二醇水溶液中得混合溶液,此时,混合溶液中六氟异丙醇和二氯甲烷的体积比为1:1,聚对二氧环己酮和聚乙二醇水溶液中聚乙二醇的质量比为2:1,将所述混合溶液以4000rpm均质搅拌至乳化完全后加入体积为所述混合溶液3倍的水固化微球,所述水的温度为5℃,制得含有聚对二氧环己酮微球的乳化液;
(2)将步骤(1)中制得的乳化液在55℃,0.08MPa条件下蒸馏50min至所述乳化液中六氟异丙醇和二氯甲烷挥发,制得悬浮液;
(3)将步骤(2)中制得的悬浮液在4000rpm下离心3min后,用体积为所述悬浮液6倍的质量分数为70%的乙醇水溶液进行洗涤,然后在100℃,功率为4kW,进料量为450mL/min条件下进行喷雾干燥,制得聚对二氧环己酮微球;
(4)按3-羟基丁酸酯和3-羟基戊酸酯的共聚物与二氯甲烷的质量体积比(g/mL)为1:100将3-羟基丁酸酯和3-羟基戊酸酯的共聚物加入二氯甲烷中至所述3-羟基丁酸酯和3-羟基戊酸酯的共聚物完全溶解,然后加入步骤(3)中制备的聚对二氧环己酮微球,搅拌后滴加到聚乙二醇水溶液中得混合溶液,此时,混合溶液中3-羟基丁酸酯和3-羟基戊酸酯的共聚物和聚乙二醇水溶液中聚乙二醇的质量比为2:1,将所述混合溶液以4000rpm均质搅拌至乳化完全后加入体积为所述混合溶液3倍的水固化微球,所述水的温度为5℃,制得含有聚对二氧环己酮为核的核-壳双层微球的乳化液;
(5)将步骤(4)中制得的乳化液在55℃,0.05MPa条件下蒸馏50min至所述乳化液中二氯甲烷挥发,制得悬浮液;
(6)将步骤(5)中制得的悬浮液在4000rpm下离心3min后,用体积为所述悬浮液6倍的质量分数为70%的乙醇水溶液进行洗涤,然后在100℃,功率为4kW,进料量为450mL/min条件下进行喷雾干燥,制得聚对二氧环己酮为核的核-壳双层微球。
实施例3
(1)按聚对二氧环己酮和六氟异丙醇的质量体积比(g/mL)为4:100将聚对二氧环己酮加入六氟异丙醇中至所述聚对二氧环己酮完全溶解,再加入二氯甲烷搅拌后,滴加到聚乙烯醇水溶液中得混合溶液,此时,混合溶液中六氟异丙醇和二氯甲烷的体积比为1:1,聚对二氧环己酮和聚乙烯醇水溶液中聚乙烯醇的质量比为1:2,将所述混合溶液以7000rpm均质搅拌至乳化完全后加入体积为所述混合溶液4倍的水固化微球,所述水的温度为1℃,制得含有聚对二氧环己酮微球的乳化液;
(2)将步骤(1)中制得的乳化液在55℃,0.06MPa条件下蒸馏60min至所述乳化液中六氟异丙醇和二氯甲烷挥发,制得悬浮液;
(3)将步骤(2)中制得的悬浮液在4000rpm下离心3min后,用体积为所述悬浮液2倍的质量分数为75%的乙醇水溶液进行洗涤,然后在100℃,功率为4kW,进料量为380mL/min条件下进行喷雾干燥,制得聚对二氧环己酮微球;
(4)按聚已内酯和二氯甲烷的质量体积比(g/mL)为4:100将聚已内酯加入二氯甲烷中至所述聚已内酯完全溶解,然后加入步骤(3)中制备的聚对二氧环己酮微球,搅拌后滴加到聚乙烯醇水溶液中得混合溶液,此时,混合溶液中聚已内酯和聚乙烯醇水溶液中聚乙烯醇的质量比为1:2,将所述混合溶液以7000rpm均质搅拌至乳化完全后加入体积为所述混合溶液4倍的水固化微球,所述水的温度为1℃,制得含有聚对二氧环己酮为核的核-壳双层微球的乳化液;
(5)将步骤(4)中制得的乳化液在55℃,0.06MPa条件下蒸馏35min至所述乳化液中二氯甲烷挥发,制得悬浮液;
(6)将步骤(5)中制得的悬浮液在4000rpm下离心3min后,用体积为所述悬浮液2倍的质量分数为75%的乙醇水溶液进行洗涤,然后在110℃,功率为4kW,进料量为380mL/min条件下进行喷雾干燥,制得聚对二氧环己酮为核的核-壳双层微球。
实施例4
(1)按聚对二氧环己酮和六氟异丙醇的质量体积比(g/mL)为10:100将聚对二氧环己酮加入六氟异丙醇中至所述聚对二氧环己酮完全溶解,再加入四氯化碳搅拌后,滴加到聚乙二醇水溶液中得混合溶液,此时,混合溶液中六氟异丙醇和四氯化碳的体积比为3:1,聚对二氧环己酮和聚乙二醇水溶液中聚乙二醇的质量比为2:1,将所述混合溶液以5000rpm均质搅拌至乳化完全后加入体积为所述混合溶液2倍的水固化微球,所述水的温度为3℃,制得含有聚对二氧环己酮微球的乳化液;
(2)将步骤(1)中制得的乳化液在55℃,0.09MPa条件下蒸馏30min至所述乳化液中六氟异丙醇和四氯化碳挥发,制得悬浮液;
(3)将步骤(2)中制得的悬浮液在4000rpm下离心3min后,用体积为所述悬浮液4倍的质量分数为70%的乙醇水溶液进行洗涤,然后在100℃,功率为4kW,进料量为420mL/min条件下进行喷雾干燥,制得聚对二氧环己酮微球;
(4)按聚乳酸和四氯化碳的质量体积比(g/mL)为10:100将聚乳酸加入四氯化碳中至所述聚乳酸完全溶解,然后加入步骤(3)中制备的聚对二氧环己酮微球,搅拌后滴加到聚乙二醇水溶液中得混合溶液,此时,混合溶液中聚乳酸和聚乙二醇水溶液中聚乙二醇的质量比为2:1,将所述混合溶液以5000rpm均质搅拌至乳化完全后加入体积为所述混合溶液2倍的水固化微球,所述水的温度为3℃,制得含有聚对二氧环己酮为核的核-壳双层微球的乳化液;
(5)将步骤(4)中制得的乳化液在60℃,0.09MPa条件下蒸馏30min至所述乳化液中四氯化碳挥发,制得悬浮液;
(6)将步骤(5)中制得的悬浮液在4000rpm下离心3min后,用体积为所述悬浮液4倍的质量分数为70%的乙醇水溶液进行洗涤,然后在120℃,功率为4kW,进料量为420mL/min条件下进行喷雾干燥,制得聚对二氧环己酮为核的核-壳双层微球。
实施例5
(1)按聚对二氧环己酮和六氟异丙醇的质量体积比(g/mL)为5:100将聚对二氧环己酮加入六氟异丙醇中至所述聚对二氧环己酮完全溶解,再加入三氯甲烷搅拌后,滴加到聚乙二醇水溶液中得混合溶液,此时,混合溶液中六氟异丙醇和三氯甲烷的体积比为2.5:1,聚对二氧环己酮和聚乙二醇水溶液中聚乙二醇的质量比为1:1,将所述混合溶液以6000rpm均质搅拌至乳化完全后加入体积为所述混合溶液5倍的水固化微球,所述水的温度为4℃,制得含有聚对二氧环己酮微球的乳化液;
(2)将步骤(1)中制得的乳化液在55℃,0.07MPa条件下蒸馏40min至所述乳化液中六氟异丙醇和三氯甲烷挥发,制得悬浮液;
(3)将步骤(2)中制得的悬浮液在4000rpm下离心3min后,用体积为所述悬浮液10倍的质量分数为72%的乙醇水溶液进行洗涤,然后在100℃,功率为4kW,进料量为350mL/min条件下进行喷雾干燥,制得聚对二氧环己酮微球;
(4)按聚乳酸-羟基乙酸共聚物和三氯甲烷的质量体积比(g/mL)为5:100将聚乳酸-羟基乙酸共聚物加入三氯甲烷中至所述聚乳酸-羟基乙酸共聚物完全溶解,然后加入步骤(3)中制备的聚对二氧环己酮微球,搅拌后滴加到聚乙二醇水溶液中得混合溶液,此时,混合溶液中聚乳酸-羟基乙酸共聚物和聚乙二醇水溶液中聚乙二醇的质量比为1:1,将所述混合溶液以6000rpm均质搅拌至乳化完全后加入体积为所述混合溶液5倍的水固化微球,所述水的温度为4℃,制得含有聚对二氧环己酮为核的核-壳双层微球的乳化液;
(5)将步骤(4)中制得的乳化液在60℃,0.07MPa条件下蒸馏40min至所述乳化液中三氯甲烷挥发,制得悬浮液;
(6)将步骤(5)中制得的悬浮液在4000rpm下离心3min后,用体积为所述悬浮液10倍的质量分数为72%的乙醇水溶液进行洗涤,然后在120℃,功率为4kW,进料量为350mL/min条件下进行喷雾干燥,制得聚对二氧环己酮为核的核-壳双层微球。
图1、图2分别为实施例1中制备的聚对二氧环己酮为核的核-壳双层微球的扫描电镜图和荧光显微镜图,由图可知,所制备的微球呈核壳结构,外层材料对聚对二氧环己酮微球进行了完好的包覆。
图3为实施例1中所用原料聚对二氧环己酮的XRD图,图4为实施例1中所用原料聚左乳酸的XRD图,图5为实施例1中制备的聚对二氧环己酮为核的核-壳双层微球的XRD图,对比三幅图可知,所制备聚对二氧环己酮为核的核-壳双层微球中核材料聚对二氧环己酮和壳材料聚左乳酸依然保持原有材料的特征晶形,说明双层微球的核、壳材料依然保持着改材料原有的特性。
图6为实施例1中制备的聚对二氧环己酮微球的粒径分布图,由图可知,所制备出的聚对二氧环己酮微球的平均粒径为432nm。
图7为实施例1中制备的聚对二氧环己酮为核的核-壳双层微球的粒径分布图,由图可知,所制备出的聚对二氧环己酮为核的核-壳双层微球的平均粒径为642nm。
本发明中,在制备聚对二氧环己酮为核的核-壳双层微球过程中,聚对二氧环己酮微球和物质B的添加量可根据实际需求进行添加。
最后说明的是,以上优选实施例仅用以说明本发明的技术方案而非限制,尽管通过上述优选实施例已经对本发明进行了详细的描述,但本领域技术人员应当理解,可以在形式上和细节上对其作出各种各样的改变,而不偏离本发明权利要求书所限定的范围。
Claims (7)
1.一种聚对二氧环己酮为核的核-壳双层微球的制备方法,其特征在于,包括如下步骤:
(1)将聚对二氧环己酮加入六氟异丙醇中至所述聚对二氧环己酮完全溶解,再加入溶剂A搅拌后,滴加到乳化剂中得混合溶液,所述混合溶液经分散、固化后,制得含有聚对二氧环己酮微球的乳化液;所述聚对二氧环己酮和六氟异丙醇的质量体积比为1~10:100;所述六氟异丙醇与溶剂A的体积比为1:1~3:1;所述乳化剂为聚乙烯醇水溶液或聚乙二醇水溶液中的一种,所述聚对二氧环己酮和所述乳化剂中溶质的质量比为2:1~1:2;所述质量体积比的单位为g/mL;
(2)将步骤(1)中制得的乳化液进行负压蒸馏处理至所述乳化液中六氟异丙醇和溶剂A挥发,制得悬浮液;
(3)将步骤(2)中制得的悬浮液进行离心、洗涤、干燥后,制得聚对二氧环己酮微球;
(4)将物质B加入溶剂A中至所述物质B完全溶解,然后加入步骤(3)中制备的聚对二氧环己酮微球,搅拌后滴加到乳化剂中得混合溶液,所述混合溶液经分散、固化后,制得含有聚对二氧环己酮为核的核-壳双层微球的乳化液;所述物质B和溶剂A的质量体积比为1~10:100;所述乳化剂为聚乙烯醇水溶液或聚乙二醇水溶液中的一种,所述物质B和所述乳化剂中溶质的质量比为2:1~1:2;所述质量体积比的单位为g/mL;
(5)将步骤(4)中制得的乳化液进行负压蒸馏处理至所述乳化液中溶剂A挥发,制得悬浮液;
(6)将步骤(5)中制得的悬浮液进行离心、洗涤、干燥后,制得聚对二氧环己酮为核的核-壳双层微球;
步骤(1)和步骤(4)中,所述分散、固化具体为室温下以4000~7000rpm均质搅拌至乳化完全后加入体积为所述混合溶液2~5倍的水固化微球,所述水的温度为1~5℃;
所述溶剂A为二氯甲烷,三氯甲烷或四氯化碳中的一种或几种;所述物质B为聚乳酸、聚左乳酸、聚乳酸-羟基乙酸共聚物、聚已内酯、聚羟基丁酸酯或3-羟基丁酸酯和3-羟基戊酸酯的共聚物中的一种或几种。
2.如权利要求1所述的一种聚对二氧环己酮为核的核-壳双层微球的制备方法,其特征在于,步骤(2)中,所述负压蒸馏处理为在55℃,0.06~0.09MPa条件下蒸馏30~60min。
3.如权利要求1所述的一种聚对二氧环己酮为核的核-壳双层微球的制备方法,其特征在于,步骤(3)中,所述离心为在4000rpm下离心3min;所述洗涤用洗涤剂是质量分数为70~75%的乙醇水溶液,所述乙醇水溶液和悬浮液的体积比为10:1~2:1;所述干燥为喷雾干燥,具体条件为100℃,功率为4kW,进料量为350~450 mL /min。
4.如权利要求1所述的一种聚对二氧环己酮为核的核-壳双层微球的制备方法,其特征在于,步骤(5)中,所述负压蒸馏处理为在55~65℃,0.06~0.09MPa条件下蒸馏30~60min。
5.如权利要求1所述的一种聚对二氧环己酮为核的核-壳双层微球的制备方法,其特征在于,步骤(6)中,所述离心为在4000 r/min下离心3min;所述洗涤用洗涤剂是质量分数为70~75%的乙醇水溶液,所述乙醇水溶液和悬浮液的体积比为10:1~2:1;所述干燥为喷雾干燥,具体条件为100~120℃,功率为4kW,进料量为350~450 mL /min。
6.由权利要求1-5任一项所述的方法制备的聚对二氧环己酮为核的核-壳双层微球。
7.权利要求6所述的聚对二氧环己酮为核的核-壳双层微球在制备载药微球药物的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710138619.2A CN106727422B (zh) | 2017-03-09 | 2017-03-09 | 一种聚对二氧环己酮为核的核-壳双层微球及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710138619.2A CN106727422B (zh) | 2017-03-09 | 2017-03-09 | 一种聚对二氧环己酮为核的核-壳双层微球及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106727422A CN106727422A (zh) | 2017-05-31 |
CN106727422B true CN106727422B (zh) | 2018-10-02 |
Family
ID=58961820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710138619.2A Active CN106727422B (zh) | 2017-03-09 | 2017-03-09 | 一种聚对二氧环己酮为核的核-壳双层微球及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106727422B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112545943B (zh) * | 2020-12-20 | 2022-04-08 | 时垠(上海)生物科技有限公司 | 一种包含植物提取物的sod类化妆品添加剂 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101541313A (zh) * | 2006-10-05 | 2009-09-23 | 万能药生物有限公司 | 可注射的储库组合物及其制备方法 |
CN105106174A (zh) * | 2015-09-06 | 2015-12-02 | 烟台大学 | 一种核-壳双层微球及其制备方法 |
-
2017
- 2017-03-09 CN CN201710138619.2A patent/CN106727422B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101541313A (zh) * | 2006-10-05 | 2009-09-23 | 万能药生物有限公司 | 可注射的储库组合物及其制备方法 |
CN105106174A (zh) * | 2015-09-06 | 2015-12-02 | 烟台大学 | 一种核-壳双层微球及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN106727422A (zh) | 2017-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102034872B1 (ko) | 콜라겐 펩타이드가 함유된 폴리카프로락톤 미립구 필러 및 그 제조방법 | |
Geng et al. | Sustained release of VEGF from PLGA nanoparticles embedded thermo-sensitive hydrogel in full-thickness porcine bladder acellular matrix | |
Miladi et al. | Particles from preformed polymers as carriers for drug delivery | |
KR102034871B1 (ko) | 비타민 c가 함유된 폴리카프로락톤 미립구 필러 및 그 제조방법 | |
CN111184909B (zh) | 一种透明质酸缓释填充物及制备方法 | |
Ruan et al. | Progress in the application of sustained-release drug microspheres in tissue engineering | |
Jay et al. | Engineering of multifunctional gels integrating highly efficient growth factor delivery with endothelial cell transplantation | |
WO2016095811A1 (zh) | 一种用聚乙二醇制备丝素纳微米球的方法及其在药物控释中的应用 | |
CN102560887B (zh) | 负载维生素a和e的丝素蛋白纳米纤维膜及其制备方法 | |
Tekade et al. | Biopolymer-based nanocomposites for transdermal drug delivery | |
Wang et al. | Electrosprayed soft capsules of millimeter size for specifically delivering fish oil/nutrients to the stomach and intestines | |
CN102274163A (zh) | 一种姜黄素纳米胶束制剂及其制备方法 | |
CN109998997B (zh) | 一种利用膜乳化法制备聚酯类有机高分子微球的方法 | |
CN1698901A (zh) | 以壳聚糖及其衍生物作为药物载体负载丹参提取物 | |
Li et al. | Functional nanofibrous biomaterials of tailored structures for drug delivery—a critical review | |
WO2023179581A1 (zh) | 一种生物功能复合多孔聚酯微球及其制备方法 | |
Yu et al. | Core/shell PLGA microspheres with controllable in vivo release profile via rational core phase design | |
CN106421800A (zh) | 丝素蛋白改性凹坑结构乳酸基聚合物载药微球及制备方法 | |
JP5031001B2 (ja) | ナノスフェアの製造方法、ナノスフェア、これを含有する皮膚外用組成物および化粧料 | |
CN108912349A (zh) | 聚乳酸微球及其制备方法与在药物缓释中的应用 | |
CN106727422B (zh) | 一种聚对二氧环己酮为核的核-壳双层微球及其制备方法和应用 | |
CN110367249A (zh) | 一种具有逐级缓释功能的可降解载药膜材料及其制备方法和应用 | |
CN102988301A (zh) | 一种含贝伐单抗的长效缓释微球的制备方法 | |
Erdal et al. | Electrospun nanofibers as carriers in dermal drug delivery | |
JP7266220B2 (ja) | エスシタロプラムを含む微粒球状徐放出注射剤及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Qiuyu Inventor before: Wang Qiuyu Inventor before: Li Shirong |
|
CB03 | Change of inventor or designer information | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190321 Address after: 400714 No. 68 Fenghe Road, Beibei District, Chongqing, 2-1-2 Patentee after: Chongqing Revander Biotechnology Co., Ltd. Address before: Chongqing city Shapingba street 400038 gaotanyan No. 30 Patentee before: Wang Qiuyu |
|
TR01 | Transfer of patent right |